Lexeo Therapeutics, Inc. (LXEO) Ownership
LXEO ownership summary
as of October 18, 2026- Institutions
- 114.8% of shares outstanding
- Insiders
- 0.64% of shares outstanding
- Shares outstanding
- 82.1M
- Float
- 51.2M shares available to trade
- Short interest
- 27.35% 19.2M shares short
- Days to cover
- 13.91 short interest down 6.7% vs prior month
- Institutions 114.80%
- Insiders 0.64%
LXEO top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Suvretta Capital Management, LLC | 7.78% | 6.4M | $16.9M | +5.1M (+410.7%) | June 30, 2026 |
| 2 | Affinity Asset Advisors, LLC | 7.07% | 5.8M | $15.3M | +757,400 (+15.0%) | June 30, 2026 |
| 3 | BlackRock Inc | 6.99% | 5.7M | $15.2M | +628,584 (+12.3%) | June 30, 2026 |
| 4 | RA Capital Management, LLC | 6.09% | 5.0M | $13.2M | — | June 30, 2026 |
| 5 | HHG PLC | 6.06% | 5.0M | $13.1M | −533,206 (−9.7%) | March 31, 2026 |
| 6 | Frazier Life Sciences Management, L.P. | 5.88% | 4.8M | $12.7M | +400,000 (+9.0%) | June 30, 2026 |
| 7 | State Street Corp | 5.30% | 4.4M | $11.5M | +786,515 (+22.0%) | June 30, 2026 |
| 8 | Vestal Point Capital LP | 5.26% | 4.3M | $11.4M | −155,000 (−3.5%) | June 30, 2026 |
| 9 | Paradigm Biocapital Advisors LP | 5.09% | 4.2M | $11.0M | −2.0M (−32.5%) | June 30, 2026 |
| 10 | Jupiter Topco LLC | 4.82% | 4.0M | $10.4M | +4.0M (0.0%) | June 30, 2026 |
| 11 | Orbimed Advisors LLC | 4.81% | 3.9M | $10.4M | +345,400 (+9.6%) | June 30, 2026 |
| 12 | Citadel Advisors Llc | 4.75% | 3.9M | $10.3M | +63,571 (+1.7%) | June 30, 2026 |
| 13 | Vanguard Capital Management, LLC | 3.81% | 3.1M | $8.3M | +118,800 (+4.0%) | June 30, 2026 |
| 14 | Millennium Management LLC | 3.45% | 2.8M | $7.5M | +1.2M (+75.7%) | June 30, 2026 |
| 15 | Nantahala Capital Management, LLC | 3.17% | 2.6M | $6.9M | +1.4M (+116.7%) | June 30, 2026 |
| 16 | Woodline Partners LP | 3.05% | 2.5M | $6.6M | −250,000 (−9.1%) | June 30, 2026 |
| 17 | Balyasny Asset Management LLC | 2.94% | 2.4M | $6.4M | +823,157 (+51.8%) | June 30, 2026 |
| 18 | The Goldman Sachs Group Inc | 2.62% | 2.1M | $5.7M | +199,727 (+10.2%) | June 30, 2026 |
| 19 | Geode Capital Management, LLC | 2.13% | 1.7M | $4.6M | +234,182 (+15.5%) | June 30, 2026 |
| 20 | ADAR1 Capital Management LLC | 1.91% | 1.6M | $4.1M | +98,600 (+6.7%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 15 holders added 16.2M shares and 4 cut 2.9M.
LXEO top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.84% | 2.3M | $6.2M | — | August 31, 2026 |
| 2 | JPMorgan Small Cap Growth A | 2.57% | 2.1M | $5.6M | +514,712 (+32.3%) | August 31, 2026 |
| 3 | iShares Russell 2000 ETF | 2.26% | 1.9M | $4.9M | −21,376 (−1.1%) | September 30, 2026 |
| 4 | State Street® SPDR® S&P® Biotech ETF | 1.94% | 1.6M | $4.2M | −30,450 (−1.9%) | September 30, 2026 |
| 5 | abrdn Life Sciences Investors | 1.18% | 968K | $2.6M | +146,954 (+17.9%) | August 31, 2026 |
| 6 | Fidelity Small Cap Index | 0.95% | 777K | $2.1M | +6,523 (+0.8%) | July 31, 2026 |
| 7 | Biotech Growth Ord | 0.91% | 745K | $2.0M | +345,400 (+86.5%) | June 30, 2026 |
| 8 | JPMorgan Small Cap Blend A | 0.82% | 676K | $1.8M | +169,006 (+33.3%) | August 31, 2026 |
| 9 | iShares Russell 2000 Value ETF | 0.81% | 668K | $1.8M | +1,014 (+0.2%) | September 30, 2026 |
| 10 | Janus Global Life Science AUSD | 0.70% | 576K | $1.5M | −4,551 (−0.8%) | June 30, 2026 |
| 11 | Janus Henderson Glb Life Scn I2 USD | 0.70% | 576K | $1.5M | −2 (−0.0%) | August 31, 2026 |
| 12 | Stt Strt®SPDR®S&PKenshoNwEcosComposETF | 0.69% | 564K | $1.5M | — | September 30, 2026 |
| 13 | Janus Henderson Global Life Sciences D | 0.68% | 561K | $1.5M | — | August 31, 2026 |
| 14 | iShares Biotechnology ETF | 0.66% | 539K | $1.4M | −4,088 (−0.8%) | September 30, 2026 |
| 15 | Vanguard Russell 2000 ETF | 0.50% | 408K | $1.1M | +10,098 (+2.5%) | August 31, 2026 |
| 16 | Fidelity Extended Market Index | 0.40% | 325K | $857,047 | +92,650 (+39.9%) | August 31, 2026 |
| 17 | Fidelity Enhanced Small Cap Core ETF | 0.36% | 294K | $776,094 | +615 (+0.2%) | September 30, 2026 |
| 18 | Multi-Manager Small Cap Eq Strat Inst | 0.35% | 284K | $749,514 | +32,172 (+12.8%) | August 31, 2026 |
| 19 | Northern Small Cap Value | 0.32% | 261K | $689,328 | +261,109 (0.0%) | June 30, 2026 |
| 20 | Dimensional US Small Cap ETF | 0.31% | 254K | $670,695 | — | September 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
LXEO insider transactions
latest 18| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-06 | Richard Nolan Townsend | Sell | $5.69 | 55,000 | $312,950 |
| 2026-02-18 | Jose Manuel Otero | Sell | $6.40 | 3,016 | $19,302 |
| 2026-02-18 | Richard Nolan Townsend | Sell | $6.38 | 10,173 | $64,904 |
| 2025-11-18 | Eric Adler | Sell | $9.27 | 615 | $5,701 |
| 2025-11-18 | Richard Nolan Townsend | Sell | $9.27 | 1,127 | $10,447 |
| 2025-11-18 | Tai Sandi See | Sell | $9.27 | 386 | $3,578 |
| 2025-10-17 | Tai Sandi See | Sell | $8.94 | 3,888 | $34,759 |
| 2025-10-17 | Richard Nolan Townsend | Sell | $8.94 | 13,133 | $117,409 |
| 2025-10-17 | Jose Manuel Otero | Sell | $8.94 | 2,115 | $18,908 |
| 2025-10-17 | Eric Adler | Sell | $8.94 | 3,382 | $30,235 |
| 2025-08-18 | Eric Adler | Sell | $4.67 | 608 | $2,839 |
| 2025-08-18 | Jose Manuel Otero | Sell | $4.67 | 2,848 | $13,300 |
| 2025-08-18 | Jose Manuel Otero | Sell | $9.27 | 721 | $6,684 |
| 2025-08-18 | Richard Nolan Townsend | Sell | $4.67 | 2,735 | $12,772 |
| 2025-08-18 | Tai Sandi See | Sell | $4.67 | 382 | $1,784 |
| 2025-05-16 | Eric Adler | Sell | $2.77 | 585 | $1,620 |
| 2025-05-16 | Richard Nolan Townsend | Sell | $2.77 | 1,074 | $2,975 |
| 2025-05-16 | Tai Sandi See | Sell | $2.77 | 367 | $1,017 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
LXEO shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns LXEO
Institutional investors own 114.8% of Lexeo Therapeutics's shares and insiders 0.64%. The largest holder is Suvretta Capital Management, LLC with 7.78% of the shares (6.4M), as of June 30, 2026. Among the top 20 institutions, 15 added shares and 4 reduced their stake in the latest filings. Short interest is 27.35% of the float, or 13.91 days of average trading volume. The share count rose 203.4% since 2022.
Related: LXEO analyst forecast, LXEO key metrics. See the LXEO stock overview for the latest quote and news.
LXEO ownership FAQ
Who owns the most Lexeo Therapeutics stock?
The largest shareholders of Lexeo Therapeutics are Suvretta Capital Management, LLC (7.78%), Affinity Asset Advisors, LLC (7.07%), BlackRock Inc (6.99%), RA Capital Management, LLC (6.09%), HHG PLC (6.06%).
What percentage of Lexeo Therapeutics is owned by institutions?
Institutions hold 114.8% of Lexeo Therapeutics's shares outstanding; insiders hold 0.64%.
Which funds own Lexeo Therapeutics?
The largest fund holders of Lexeo Therapeutics are Vanguard MStar Total Stk Mkt Idx Invest (2.84%), JPMorgan Small Cap Growth A (2.57%), iShares Russell 2000 ETF (2.26%), State Street® SPDR® S&P® Biotech ETF (1.94%), abrdn Life Sciences Investors (1.18%).
What is Lexeo Therapeutics's short interest?
19.2M shares of Lexeo Therapeutics were sold short, 27.35% of the float; at the average daily volume it would take 13.91 days to cover.
Are insiders buying or selling Lexeo Therapeutics?
Of the latest 18 reported insider transactions in Lexeo Therapeutics (since May 16, 2025), 0 were purchases and 18 were sales.
How many shares of Lexeo Therapeutics are outstanding?
Lexeo Therapeutics has 82.1M shares outstanding, of which 51.2M are in the public float.